The mFlusiva vaccine for older people is the first made with the mRNA platform key to ending the coronavirus pandemic
The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic, Moderna, the manufacturer, said.
The shot, named mFlusiva, is intended for adults aged 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.
